Accepted for Publication: January 26, 2021.
Published Online: April 15, 2021. doi:10.1001/jamaophthalmol.2021.0341
Correction: This article was corrected on July 22, 2021, to fix labeling errors in Figure 2A.
Corresponding Author: Mae O. Gordon, PhD, Department of Ophthalmology and Visual Sciences, Washington University School of Medicine in St Louis, 660 S Euclid, CB 8096, St Louis, MO 63122 (gordon.mae@wustl.edu).
Author Contributions: Drs Gordon and Kass had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Kass, Heuer, Higginbotham, Parrish, Johnson, Miller, Brandt, Khanna, Quigley, Gordon.
Acquisition, analysis, or interpretation of data: Heuer, Johnson, Keltner, Huecker, Wilson, Liu, Miller, Brandt, Khanna, Soltau, Gordon.
Drafting of the manuscript: Kass, Parrish, Wilson, Liu, Khanna, Quigley, Gordon.
Critical revision of the manuscript for important intellectual content: Kass, Heuer, Higginbotham, Johnson, Keltner, Huecker, Miller, Brandt, Khanna, Soltau, Gordon.
Statistical analysis: Wilson, Liu, Miller, Gordon.
Obtained funding: Kass, Brandt, Gordon.
Administrative, technical, or material support: Kass, Heuer, Higginbotham, Johnson, Keltner, Huecker, Brandt, Khanna, Gordon.
Supervision: Kass, Parrish, Soltau, Gordon.
Other—Served on study Executive Committee: Brandt.
Conflict of Interest Disclosures: Dr Kass reported receiving grants from Merck, the National Institutes of Health, Pfizer, and Research to Prevent Blindness during the conduct of the study and owning stock options in Smartlens outside the submitted work. Dr Heuer reported receiving personal fees from Washington University as a subcontractor for the National Eye Institute and the National Institutes of Health during the conduct of the study and receiving personal fees from Advanced Clinical (for serving as consultant to Google) and InnFocus outside the submitted work. Dr Higginbotham reported receiving grants from the National Eye Institute and being a subcontractor for Washington University during the conduct of the study. Ms Huecker reported receiving grants from the National Eye Institute during the conduct of the study and outside the submitted work. Mr Wilson reported receiving grants from the National Eye Institute during the conduct of the study. Dr Liu reported receiving grants from the National Institutes of Health during the conduct of the study and receiving consulting fees from Mesoblast outside the submitted work. Mr Miller reported receiving grants from the National Institutes of Health during the conduct of the study and receiving grants from the National Institutes of Health and the Patient-Centered Outcomes Research Institute and personal fees from General Dynamics (US Department of Defense) and the National Institutes of Health outside the submitted work. Dr Brandt reported receiving grants from the National Eye Institute during the conduct of the study and receiving consulting fees from Aerie Pharmaceuticals and Graybug Vision outside the submitted work. Dr Soltau reported receiving grants from the National Institutes of Health during the conduct of the study. Dr Gordon reported receiving grants from the National Eye Institute during the conduct of the study. No other disclosures were reported.
Funding/Support: This study was supported by grant UL1 TR002345 (Drs Liu and Gordon and Mr Miller) from the Institute of Clinical and Translational Sciences; grants U10 EY09341 (Dr Gordon), U10 EY09370 (Dr Kass), UG1 EY025180 (Dr Kass, chairman), UG1 EY025181 (Dr Gordon, clinical center), UG1 EY025182 (Dr Gordon, coordinating center), and UG1 EY025183 (Dr Kass, resource centers) from the National Eye Institute; grant P30 EY002687 (Dr Gordon, Ms Huecker, and Mr Wilson) from the National Institutes of Health; and an unrestricted grant from Research to Prevent Blindness.
Role of the Funder/Sponsor: The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Group Information: The Ocular Hypertension Study Group Investigators, Coordinators, and Executive Committee are listed in Supplement 2.
1.Kass
MA , Heuer
DK , Higginbotham
EJ ,
et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma.
Arch Ophthalmol. 2002;120(6):701-713. doi:
10.1001/archopht.120.6.701
PubMedGoogle ScholarCrossref 3.Gordon
MO , Torri
V , Miglior
S ,
et al; Ocular Hypertension Treatment Study Group; European Glaucoma Prevention Study Group. Validated prediction model for the development of primary open-angle glaucoma in individuals with ocular hypertension.
Ophthalmology. 2007;114(1):10-19. doi:
10.1016/j.ophtha.2006.08.031
PubMedGoogle Scholar 5.Kass
MA , Gordon
MO , Gao
F ,
et al; Ocular Hypertension Treatment Study Group. Delaying treatment of ocular hypertension: the ocular hypertension treatment study.
Arch Ophthalmol. 2010;128(3):276-287. doi:
10.1001/archophthalmol.2010.20
PubMedGoogle Scholar 7.Gordon
MO , Higginbotham
EJ , Heuer
DK ,
et al; Ocular Hypertension Treatment Study. Assessment of the impact of an endpoint committee in the Ocular Hypertension Treatment Study.
Am J Ophthalmol. 2019;199:193-199. doi:
10.1016/j.ajo.2018.11.006
PubMedGoogle ScholarCrossref 10.Sun J. The Statistical Analysis of Interval-Censored Failure Time Data. Springer; 2006.
11.Hodapp
E , Parrish
RK
II , Anderson
DR . Clinical Decisions in Glaucoma. 1st ed. Mosby; 1993.
14.Oskarsdottir
SE , Heijl
A , Midlov
P , Bengtsson
B . Lifetime risk of visual impairment resulting from glaucoma in patients initially followed up for elevated intraocular pressure.
Ophthalmol Glaucoma. 2020;3(1):60-65. doi:
10.1016/j.ogla.2019.09.002
PubMedGoogle ScholarCrossref